• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

eFoodSafety.Com, Inc. Commences Human Clinical Trials on Cinnergen Diabetes Product

Posted on: Wednesday, 8 February 2006, 12:00 CST

Patricia Gruden, President/CEO of eFoodSafety.com, Inc. (OTCBB:EFSF) announced today that human clinical trials have begun on Cinnergen(TM), an all natural whole food liquid nutritional supplement designed to effectively metabolize glucose.

The Cinnergen(TM) clinical trial is a 50 patient randomized double blind study to determine the efficacy in diabetics. "With the large number of patients in this study, this clinical trial meets the standards for all major pharmaceutical companies that undergo human clinical studies to determine efficacy. If the results are favorable, this study will be statistically significant and peer reviewed by the medical profession, as well as be submitted for publication," stated Dr. David J. Miller, Executive Director of Bucks Country Clinical Research, Inc. (BCCR) (http://bccrinc.com/), an FDA clinical research facility. Richard M. Goldfarb, M.D., FACS, a Director of eFoodSafety.com, Inc., and President of MedElite, Inc., a wholly-owned subsidiary of eFoodSafety.com, Inc., is the Medical Director of Research & Development at BCCR.

Cinnergen(TM) is made up from 15 whole foods, which contains no fats, carbohydrates, sugar or calories and has been designed to regulate blood sugar in the body. According to the American Diabetes Association, 16 million people are affected by diabetes, 6 to 8 million are undiagnosed and over 790,000 new cases are diagnosed per year. The rate of diabetes in the United States increased 49% from 1990 to 2000 and is estimated to increase by 165% by 2050. Diabetes contributes to the deaths of more than 213,000 Americans each year (American Diabetes Association - www.diabetes.org). According to the Centers for Disease Control and Prevention (CDC), the total direct and indirect costs of diabetes in the United States as calculated in 2002 were estimated at $132 billion and growing.

"We are undergoing this human clinical trial to properly document the effectiveness of Cinnergen(TM) in diabetics. In keeping with the company's philosophy of introducing natural and revolutionary alternatives to patients of all types, most diabetics will now be able to utilize this all-natural, whole food and clinically proven product without the cost and worrisome side effects of prescription medications," stated Mrs. Ross-Gruden.

About eFoodSafety.com, Inc.

eFoodSafety.com, Inc. is dedicated to improving food and health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and most recently became a distributor for Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes.

Safe Harbor Forward-Looking Statements

Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements invoke risk and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.

Source: Business Wire

More News in this Category